The cost-effectiveness of vaccinating infants with PCV-13 in China was estimated to be 21 times greater when the indirect effects of vaccination in reducing invasive pneumococcal disease and hospitalized cases of pneumonia in older (unvaccinated) individuals was taken into account — with costs per quality of life-year gained (QALY) of around US$564 (Y3,777) vs. $11,836 (Y79,204) when only the direct impact on vaccinated children is considered.
Full Citation:
Shen K, Wasserman M, Liu D et al.. 2018. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China. PLoS One. 13(7).
Title of Article: Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China
Author(s): Shen K, Wasserman M, Liu D et al.
Publication Year: 2018
Publication Name: PLoS One
Publication Volume: 13(7)
Publication Source URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059448/pdf/pone.0201245.pdf
DOI (Digital Object Identifier): 10.1371/journal.pone.0201245
Topics: Economics & Return on Investment
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Countries: China
WHO Regions: Western Pacific